The Patterns and Risk Factors for Antidepressant Drug Prescription in Thyroid Cancer Patients and Survivors: Analysis Based on the Korean National Health Insurance Service Database.
Kang YE et al. Thyroid. 2026
Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment.
Minaldi E et al. J Clin Endocrinol Metab. 2026
Health-related Quality of Life with Encorafenib plus Binimetinib for BRAFV600E Thyroid Cancer.
Kiyota N et al. Eur Thyroid J. 2026
Initial Evaluation of Radioiodine Therapy Using Imaging for Long-term Prognosis in Thyroid Cancer: A Retrospective Study.
Nakatani R et al. J Clin Endocrinol Metab. 2026
Approach to the patient: Oncocytic thyroid cancer.
Finnegan EA et al. J Clin Endocrinol Metab. 2026
Landscape of Genomic Mechanisms of Resistance to Selective RET Inhibitors in RET-Altered Solid Tumors: Analysis of the RETgistry Global Consortium.
Waliany S et al. Clin Cancer Res. 2026
Molecular Profiling and Real-world Outcomes of BRAF V600E-Mutated Papillary Thyroid Cancer.
Chirra M et al. Clin Cancer Res. 2026
Real-world external control arm for the single-arm LIBRETTO-001 trial of selpercatinib in RET-mutation-positive medullary thyroid cancer: RECALIB-RET.
Hadoux J et al. ESMO Open. 2026
Precautionary Behaviors and Side Effects after Radioiodine for Thyroid Disease: A Prospective Cohort Study.
Yielder R et al. Thyroid. 2026
TERT promoter mutations and recurrence patterns in differentiated thyroid carcinoma.
Ryu HJ et al. Endocr Relat Cancer. 2026
Real-world data show limited efficacy of sequential cabozantinib treatment in RAIR-(P)DTC.
Machlah YM et al. Endocr Relat Cancer. 2026
Anlotinib Plus Sintilimab for BRAFV600E Negative Unresectable or Metastatic Anaplastic Thyroid Carcinoma: A Single-Center, Single-Arm, Phase 2 Trial.
Gui L et al. Thyroid. 2026
ALK Inhibition Prolongs Survival in a Mouse Model of ALK-Positive Anaplastic Thyroid Cancer.
Machlah YM et al. Thyroid. 2026
Long-term Survivors of Anaplastic Thyroid Cancer: A Genomic Predictive Model.
Greenspun BC et al. J Clin Endocrinol Metab. 2026
Exposure to GLP-1RA and risk of structural progression in differentiated thyroid cancer.
Patrizio A et al. J Clin Endocrinol Metab. 2026
Real-World Experience with Lenvatinib plus Pembrolizumab in Metastatic BRAF Wild-Type Anaplastic Thyroid Carcinoma.
Hamidi S et al. Thyroid. 2026
Defining the ATA-2025 'consider RAIT' zone in older patients with N1b PTC.
Wang Z et al. Endocr Relat Cancer. 2026
FOSL1 Orchestrates Epigenetic Reprogramming of Anaplastic Thyroid Cancer and Suppresses Natural Killer Cell-Mediated Antitumor Immunity.
Huo Y et al. Cancer Res. 2026
Pre-Radioiodine Thyrotropin Thresholds During Withdrawal Preparation in Differentiated Thyroid Cancer after Total Thyroidectomy: A Systematic Review and Meta-Analysis.
Rojas T et al. Thyroid. 2026
Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues.
Hamidi S et al. J Clin Endocrinol Metab. 2026
Nrf2 shapes response to lysosomal inhibition of radiation-induced senescent thyroid cancer cells.
Mazzoleni B et al. Endocr Relat Cancer. 2026
Next-generation sequencing of targetable gene fusions in radioiodine-refractory thyroid cancer: a multicenter study.
Yoo J et al. Endocr Relat Cancer. 2025
Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus.
Ryška A et al. Eur Thyroid J. 2025
Long-Term Clinical Outcomes of Patients with Differentiated Thyroid Cancer Treated with Lenvatinib: Results from Real-World Practice in Japan.
Onaga R et al. Thyroid. 2025
Targeting Src tyrosine kinase to enhance radioiodide uptake in breast cancer.
Poole VL et al. Endocr Relat Cancer. 2025
Thyroid Cancer Survivors Experience Persistent Symptoms and Health-Related Quality-of-Life Deficits 12 Months Following Surgery.
O'Neill CJ et al. Thyroid. 2025
Development and validation of long-acting recombinant human TSH using SAFA technology.
Kim D et al. Endocr Relat Cancer. 2025
2025 American Thyroid Association Management Guidelines for Adult Patients with Differentiated Thyroid Cancer.
Ringel MD et al. Thyroid. 2025
Predictive factors of radioiodine ablation success: results from a MEDIRAD prospective clinical study for thyroid cancer.
Taprogge J et al. Eur Thyroid J. 2025
TSHR in thyroid cancer: bridging biological insights to targeted strategies.
Xu S et al. Eur Thyroid J. 2025
Differentiated thyroid cancer in two European referral centres: impact of different diagnostic and therapeutic strategies.
Ceruti D et al. Eur Thyroid J. 2025
Clinical and Pathological Factors Associated with Disease Persistence in Pediatric Patients with Differentiated Thyroid Carcinoma.
De Leo S et al. Thyroid. 2025
Contribution of Germline Predisposition to Pediatric Thyroid Cancer.
Harrison C et al. Clin Cancer Res. 2025
Thyroid Carcinoma in Birt-Hogg-Dubé Syndrome: Case Series and Review of Literature.
Vaid S et al. Thyroid. 2025
Risk-adapted therapy in pediatric thyroid cancer: initial experience from a national reference program by the MET group.
Kuhlen M et al. Eur Thyroid J. 2025
Approach to the Patient With Thyroid Cancer: Selection and Management of Candidates for Lobectomy.
Robenshtok E et al. J Clin Endocrinol Metab. 2025
Clinical outcomes of malignant pleural effusion in patients with lung metastases from differentiated thyroid cancer.
Kim CA et al. Endocr Relat Cancer. 2025
Clinical differences and surgery in follicular vs oncocytic thyroid carcinomas.
Xiang J et al. Endocr Relat Cancer. 2025
Impact of molecular tests and precision oncology on patients with advanced thyroid carcinomas in a referral center: the OrienTHYring real-world study.
Colombo E et al. ESMO Open. 2025
TP53 Alterations Are Associated With Poor Response to Lenvatinib in Patients With Advanced Thyroid Cancer.
Cirello V et al. J Clin Endocrinol Metab. 2025
A Systematic Review of Absorbed Doses and Response in Patients Treated with Radioiodine for Differentiated Thyroid Cancer.
Taprogge J et al. Thyroid. 2025
Management of Adverse Events During Treatment for Advanced Thyroid Cancer.
Roberts TJ et al. Thyroid. 2025
Thyroglobulin Cutoffs after Total Thyroidectomy Without Radioiodine in Low- to Intermediate-Risk Thyroid Cancer: A Multicenter Cohort Study.
Kim M et al. Thyroid. 2025
Are Total Thyroidectomy and Adjuvant Radioactive Iodine Treatment Required in All Patients with N1b Intermediate-High Risk Papillary Thyroid Carcinoma?
Fujiwara T et al. Thyroid. 2025
Clinical relevance of the thyroid differentiation score (TDS) in benign and malignant thyroid tumors.
Muzza M et al. Endocr Relat Cancer. 2025
Dynamic risk stratification in patients with follicular thyroid carcinoma treated with lobectomy.
Yamazaki H et al. Eur Thyroid J. 2025
Genetic modification of the AJCC classification of papillary thyroid cancer: an international, multicentre, retrospective cohort study.
Xing M et al. Lancet Oncol. 2025
Dynamic Risk Assessment Using Unstimulated Serum Thyroglobulin Level and Thyroglobulin Doubling Rate after Total Thyroidectomy for Papillary Thyroid Carcinoma.
Ito Y et al. Thyroid. 2025
Anlotinib in progressive RAI-refractory differentiated thyroid cancer: long-term results and PET/CT prognostic markers.
Sun D et al. Endocr Relat Cancer. 2025
Lenvatinib as an urgent initial therapy in thyroid cancer with remarkable laryngotracheal invasion.
Katoh H et al. Eur Thyroid J. 2025